Eli Lilly and Company (LLY) announced the successful completion of its acquisition of Verve Therapeutics. (VERV). Verve is a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LLY:
- Eli Lilly receives CHMP opinion recommending donanemab for Alzheimer’s
- Eli Lilly and Incyte’s Rheumatoid Arthritis Study: A Potential Market Game-Changer
- Eli Lilly’s LOXO-783 Study: A Potential Game-Changer in Cancer Treatment
- Eli Lilly’s Lebrikizumab Study: A Promising Step in Pediatric Dermatology
- Eli Lilly and Loxo Oncology’s Promising Phase 3 Study in CLL/SLL: A Potential Game-Changer?